ESSA Pharma (EPIX) Competitors $1.88 +0.01 (+0.27%) As of 07/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPIX vs. ALT, AMRN, PVLA, RCKT, IVA, ALDX, NGNE, CAPR, RNAC, and OLMAShould you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Altimmune (ALT), Amarin (AMRN), Palvella Therapeutics (PVLA), Rocket Pharmaceuticals (RCKT), Inventiva (IVA), Aldeyra Therapeutics (ALDX), Neurogene (NGNE), Capricor Therapeutics (CAPR), Cartesian Therapeutics (RNAC), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. ESSA Pharma vs. Its Competitors Altimmune Amarin Palvella Therapeutics Rocket Pharmaceuticals Inventiva Aldeyra Therapeutics Neurogene Capricor Therapeutics Cartesian Therapeutics Olema Pharmaceuticals Altimmune (NASDAQ:ALT) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do institutionals & insiders have more ownership in ALT or EPIX? 78.1% of Altimmune shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 4.1% of Altimmune shares are held by company insiders. Comparatively, 15.5% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, ALT or EPIX? Altimmune has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Is ALT or EPIX more profitable? ESSA Pharma has a net margin of 0.00% compared to Altimmune's net margin of -451,200.00%. ESSA Pharma's return on equity of -23.48% beat Altimmune's return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-451,200.00% -65.44% -58.43% ESSA Pharma N/A -23.48%-22.86% Which has better valuation and earnings, ALT or EPIX? ESSA Pharma has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$20K16,545.83-$95.06M-$1.26-3.24ESSA PharmaN/AN/A-$28.54M-$0.63-2.98 Do analysts prefer ALT or EPIX? Altimmune currently has a consensus price target of $18.20, indicating a potential upside of 346.08%. ESSA Pharma has a consensus price target of $2.00, indicating a potential upside of 6.38%. Given Altimmune's stronger consensus rating and higher probable upside, equities analysts plainly believe Altimmune is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor ALT or EPIX? In the previous week, Altimmune had 6 more articles in the media than ESSA Pharma. MarketBeat recorded 8 mentions for Altimmune and 2 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 0.93 beat Altimmune's score of 0.33 indicating that ESSA Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral ESSA Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryESSA Pharma beats Altimmune on 9 of the 16 factors compared between the two stocks. Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPIX vs. The Competition Export to ExcelMetricESSA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.01M$2.49B$5.69B$9.50BDividend YieldN/A1.65%4.58%4.01%P/E Ratio-2.989.0528.1020.05Price / SalesN/A612.51432.4490.07Price / CashN/A165.2136.2258.56Price / Book0.675.168.665.87Net Income-$28.54M$30.99M$3.25B$258.55M7 Day PerformanceN/A7.74%4.23%3.74%1 Month Performance8.05%16.27%10.52%11.75%1 Year Performance-64.79%-1.88%34.41%18.03% ESSA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPIXESSA Pharma0.939 of 5 stars$1.88+0.5%$2.00+6.4%-65.3%$83.01MN/A-2.9850ALTAltimmune2.1026 of 5 stars$4.05-0.7%$18.20+349.4%-39.0%$330.92M$20K0.0050AMRNAmarin0.2434 of 5 stars$15.55-1.7%$12.00-22.8%-2.7%$327.58M$228.61M-4.27360Positive NewsUpcoming EarningsPVLAPalvella Therapeutics1.4301 of 5 stars$31.00+5.0%$47.50+53.2%N/A$326.25M$42.81M0.00N/ARCKTRocket Pharmaceuticals4.8425 of 5 stars$3.13+3.0%$18.60+494.2%-87.9%$324.63MN/A-1.19240Trending NewsAnalyst ForecastAnalyst RevisionGap DownIVAInventiva3.3908 of 5 stars$3.21-5.3%$10.40+224.0%+37.5%$324.29M$9.95M0.00100Positive NewsGap DownALDXAldeyra Therapeutics2.5136 of 5 stars$5.39flat$9.50+76.3%+26.4%$322.84MN/A-5.5610Upcoming EarningsGap UpNGNENeurogene3.5663 of 5 stars$21.66-3.0%$46.17+113.1%-46.8%$318.61M$930K0.0090CAPRCapricor Therapeutics2.7488 of 5 stars$6.27-8.9%$22.56+259.7%+59.4%$314.26M$22.27M-4.42101Trending NewsGap UpRNACCartesian Therapeutics2.3061 of 5 stars$12.05+1.8%$40.00+232.0%-19.6%$307.30M$38.91M0.0064News CoveragePositive NewsGap UpOLMAOlema Pharmaceuticals2.4168 of 5 stars$4.59+4.1%$24.50+433.8%-67.9%$301.74MN/A0.0070 Related Companies and Tools Related Companies Altimmune Alternatives Amarin Alternatives Palvella Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Inventiva Alternatives Aldeyra Therapeutics Alternatives Neurogene Alternatives Capricor Therapeutics Alternatives Cartesian Therapeutics Alternatives Olema Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPIX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPIX Stock Alerts